Tag: ai-driven rare disease patient finder market growth

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for AI-powered platforms designed to identify patients with rare diseases has experienced significant expansion. Projections indicate a substantial increase from $1.62 billion in 2025 to $2.11 billion in 2026, reflecting a compound annual growth rate of 29.9%. This upward trajectory in the historical period stems from several key factors, including the greater accessibility of electronic health records, the early integration of data analytics into clinical research endeavors, the broadening scope of genomic databases, a heightened emphasis on orphan diseases, and the nascent application of artificial intelligence in facilitating clinical trial recruitment.

The market for AI-powered rare disease patient identification is projected for significant expansion soon, reaching an estimated $5.95 billion by 2030 with a compound annual growth rate (CAGR) of 29.6%. Factors propelling this growth include heightened investment in precision medicine initiatives, a greater need for accelerated clinical trial participant recruitment, the broadened application of real-world evidence analysis, augmented partnerships between healthcare and life sciences organizations, and increased governmental backing for rare disease advancements. Key developments anticipated during this period involve greater adoption of AI algorithms for pinpointing patients, more comprehensive integration of diverse health data sources, enhanced automation in clinical trial recruitment processes, the proliferation of precision patient matching services, and a strengthened commitment to facilitating rare disease research.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Expansion Drivers: What Is Shaping Future Growth?

The expansion of artificial intelligence (AI) powered tools for identifying patients with rare diseases is anticipated to be significantly boosted by the growing adoption of digital health and telemedicine. These technologies, encompassing a range of electronic tools, software, and devices for health monitoring and management, along with remote healthcare delivery through telecommunication means like video conferencing and mobile applications, are becoming increasingly favored. This heightened interest stems from both patients and healthcare professionals looking for more accessible, efficient, and time-conscious healthcare options. AI systems designed to find rare disease patients play a crucial role in supporting these digital and remote healthcare approaches by precisely pinpointing individuals, facilitating remote patient observation, enabling prompt virtual medical appointments, and offering tailored treatment plans. Supporting these advancements, a report from the Organisation for Economic Co operation and Development in November 2025 indicated that member nations have advanced their efforts in broadening access to electronic health records (EHRs). Furthermore, in 2024, the average availability of online digital health services across countries with comparable data stood at 82%, a rise from 79% observed in 2023. Consequently, the escalating embrace of digital health and telemedicine is a key factor fueling the market growth for AI-driven rare disease patient finder solutions.

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Segment Landscape: Which Areas Lead Market Development?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Strategic Trends: What Is Defining The Next Phase Of Growth?

In the landscape of the AI-driven rare disease patient finder market, leading entities are prioritizing the creation of innovative technological solutions, such as precision patient recruitment platforms. These advancements aim to bolster the precision, rapidity, and effectiveness of pinpointing suitable candidates for rare disease clinical studies. The ultimate goal is to shorten enrollment periods and elevate the likelihood of trial success. A precision patient recruitment solution represents a sophisticated, technology-enabled strategy that leverages sophisticated algorithms alongside real-world data to precisely locate and connect with individuals who align with the precise inclusion and exclusion criteria of a given clinical trial. As a case in point, in April 2024, Citeline, an American enterprise renowned for its business intelligence and data analytics capabilities, introduced its Citeline PatientMatch platform. This innovative tool integrates cutting-edge algorithms with an extensive repository of real-world data, encompassing laboratory results, biomarker information, and electronic health records sourced from more than 400 healthcare institutions. Its purpose is to empower both trial sponsors and researchers by facilitating the prompt and effective identification of eligible participants, thereby optimizing the enrollment process and accommodating intricate and varied study designs across a spectrum of medical disciplines.

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Industry Leaders And Market Competition

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Access The Complete Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Regional Analysis And Leading Geography

North Americawas the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Increase Between 2026 And 2030?

Over recent years, the market size for the artificial intelligence (AI)-driven rare disease patient finder has expanded significantly. It is projected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, with a compound annual growth rate (CAGR) of 29.9%. Factors contributing to this historical growth include the growing access to electronic health records, the nascent application of data analytics in clinical research, the proliferation of genomic databases, an elevated focus on orphan diseases, and the initial integration of AI into trial recruitment processes.

The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience substantial growth in the coming years. It is anticipated to expand to $5.95 billion by 2030, achieving a compound annual growth rate (CAGR) of 29.6%. The expansion during this forecast period can be attributed to increased investments in precision medicine research, a rising demand for expedited clinical trial enrollment, the broadening scope of real-world evidence analytics, growing collaboration between healthcare and life sciences firms, and enhanced regulatory support for rare disease innovation. Major developments expected in the forecast period include the increasing adoption of AI-based patient identification algorithms, greater integration of multi-source health data, rising automation of clinical trial recruitment, the expansion of precision patient matching platforms, and an elevated focus on enabling rare disease research.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp

What Influential Factors Are Boosting The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Demand?

The growing embrace of digital health and telemedicine is projected to stimulate the expansion of the artificial intelligence (AI)-driven rare disease patient finder market moving forward. Digital health refers to employing technology, software, and electronic tools to monitor, manage, and improve overall health and wellness. Telemedicine, on the other hand, involves delivering healthcare services remotely through telecommunications technology, such as video calls, mobile applications, and online platforms. This increasing acceptance of digital health and telemedicine is attributed to patients and providers seeking healthcare solutions that are convenient, time-efficient, and easily accessible. The artificial intelligence (AI)-driven rare disease patient finder supports digital health and telemedicine by precisely identifying patients, enabling remote monitoring, facilitating timely virtual consultations, and providing personalized care. For instance, in November 2025, the Organisation for Economic Co operation and Development, a France-based intergovernmental organization, reported that OECD countries have progressed in widening access to EHRs. In 2024, the average availability of online digital health services reached 82%, marking an increase from 79% in 2023 among countries with comparable data. Therefore, the increasing adoption of digital health and telemedicine is driving the growth of the artificial intelligence (AI)-driven rare disease patient finder market.

Which Segment Divisions Form The Structure Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

What Trends Are Influencing The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Companies operating significantly within the AI-driven rare disease patient finder market are concentrating on developing technological advancements, such as precision patient recruitment solutions. This focus aims to improve the accuracy, speed, and efficiency of identifying suitable patients for rare disease clinical trials, while also reducing recruitment timelines and enhancing trial success rates. A precision patient recruitment solution represents a technology-driven method that employs advanced algorithms and real-world data to precisely identify and engage patients who fulfill specific clinical trial eligibility criteria. For instance, in April 2024, Citeline, a US-based company focused on business intelligence and data analytics, launched Citeline PatientMatch. This platform combines advanced algorithms with comprehensive real-world data, including lab results, biomarkers, and electronic medical records from over 400 hospitals and health systems, to assist sponsors and investigators in identifying eligible patients for clinical trials efficiently and promptly, streamlining enrollment, and supporting diverse and complex study protocols across various therapeutic areas.

Who Are The Firms Contributing To The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Ecosystem?

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Access The Complete Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

What Is The Largest Regional Market In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company

Ai In Medical Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report

Artificial Intelligence Ai In Clinical Trials Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-clinical-trials-global-market-report

Artificial Intelligence In Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Expected To Change From 2026 To 2030?

The artificial intelligence (AI)-driven rare disease patient finder market size has witnessed exponential growth in recent years. It is projected to expand from $1.62 billion in 2025 to $2.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 29.9%. The growth observed in previous periods is attributable to the increasing availability of electronic health records, the early adoption of data analytics in clinical research, the expansion of genomic databases, a rising focus on orphan diseases, and the initial use of AI in trial recruitment.

The market for artificial intelligence (AI)-driven rare disease patient finders is projected to experience rapid expansion in the coming years. This market is anticipated to reach $5.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.6%. This anticipated growth stems from several factors, including heightened investments in precision medicine research, an escalating need for quicker clinical trial enrollment, the broadening scope of real-world evidence analytics, increased partnerships between healthcare and life sciences companies, and stronger regulatory backing for rare disease advancements. Key trends predicted for this period involve a greater adoption of AI-based patient identification algorithms, an increasing integration of health data from multiple sources, enhanced automation in clinical trial recruitment processes, the proliferation of precision patient matching platforms, and a reinforced emphasis on facilitating rare disease research.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

Which Primary Drivers Are Impacting The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Growth?

The future expansion of the artificial intelligence (AI)-driven rare disease patient finder market is anticipated, propelled by the growing adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments for monitoring, managing, and enhancing health and well-being. Telemedicine involves providing healthcare services remotely via telecommunications technology, including video consultations, mobile applications, and online platforms. This rising acceptance of digital health and telemedicine stems from both patients and providers seeking healthcare solutions that are convenient, save time, and are easily accessible. The artificial intelligence (AI)-driven rare disease patient finder aids digital health and telemedicine through precise patient identification, facilitation of remote monitoring, prompt virtual consultations, and customized care. For example, in November 2025, the Organisation for Economic Co operation and Development, an intergovernmental organization headquartered in France, noted that OECD nations have advanced in broadening access to Electronic Health Records (EHRs). The average availability of online digital health services in 2024 reached 82%, marking an increase from 79% in 2023 across countries with comparable data. Consequently, the growing adoption of digital health and telemedicine is propelling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.

What Are The Key Segment Divisions In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Segment Structure?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

Which Trends Are Shaping Growth In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Companies operating within the AI-driven rare disease patient finder market are primarily focused on advancing technological capabilities, such as precision patient recruitment solutions. This effort is designed to improve the accuracy, speed, and overall efficiency of pinpointing eligible patients for rare disease clinical trials, thereby reducing recruitment timelines and elevating trial success rates. A precision patient recruitment solution represents a technology-driven methodology that utilizes advanced algorithms and real-world data to accurately identify and engage patients who fulfill specific clinical trial eligibility requirements. As an illustration, in April 2024, Citeline, a US-based business intelligence and data analytics company, introduced Citeline PatientMatch. This platform merges sophisticated algorithms with comprehensive real-world data, encompassing lab results, biomarkers, and electronic medical records from over 400 hospitals and health systems, to aid sponsors and investigators in efficiently finding eligible patients for clinical trials, streamlining the enrollment process, and supporting varied and intricate study protocols across multiple therapeutic areas.

Which Organizations Are Engaged In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Get The Full Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

Which Region Holds The Highest Market Share In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company

Artificial Intelligence In Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-cancer-diagnostics-global-market-report

Ai In Medical Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report

Artificial Intelligence Ai In Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-clinical-trials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market At The End Of The 2026–2030 Forecast Period?

The artificial intelligence (AI)-driven rare disease patient finder market has experienced substantial expansion in recent years. This market is expected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 29.9%. The historical growth within this sector can be linked to factors such as the growing availability of electronic health records, the early integration of data analytics in clinical research, the expansion of genomic databases, an increased focus on orphan diseases, and the initial deployment of AI in trial recruitment.

The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $5.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.6%. Several factors are contributing to this growth during the forecast period, including higher investments in precision medicine research, an increasing need for more rapid clinical trial enrollment, the broadened scope of real-world evidence analytics, enhanced collaboration among healthcare and life sciences entities, and greater regulatory encouragement for innovations in rare diseases. Key trends foreseen for this period encompass the expanded deployment of AI-based patient identification algorithms, the growing incorporation of multi-source health data, increased automation in clinical trial recruitment processes, the development of precision patient matching platforms, and a heightened emphasis on facilitating rare disease research.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp

Which Market Drivers Are Supporting The Expansion Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The market for artificial intelligence (AI)-driven rare disease patient finders is anticipated to expand, driven by the growing adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments to oversee, control, and enhance health and well-being. Meanwhile, telemedicine involves providing healthcare remotely through telecommunications, utilizing tools like video consultations, mobile applications, and web platforms. This rising acceptance stems from both patients and healthcare providers seeking convenient, efficient, and easily accessible healthcare options. Artificial intelligence (AI)-driven rare disease patient finders bolster digital health and telemedicine efforts by precisely identifying patients, facilitating remote oversight, prompt virtual consultations, and tailored treatment plans. For example, in November 2025, the France-based intergovernmental organization, Organisation for Economic Co operation and Development, reported advancements in EHR access within OECD countries. Data from comparable countries showed that in 2024, the average availability of online digital health services reached 82%, an increase from 79% in 2023. Consequently, the growing embrace of digital health and telemedicine is fueling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.

What Segment Types Make Up The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

What Trends Are Advancing Progress In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the AI-driven rare disease patient finder market are prioritizing the creation of innovative technologies, specifically precision patient recruitment solutions. These efforts aim to improve the accuracy, speed, and efficiency with which suitable participants are located for rare disease clinical trials, thereby simultaneously shortening recruitment periods and elevating trial success rates. A precision patient recruitment solution represents a technology-led method that leverages sophisticated algorithms and real-world data to precisely pinpoint and connect with patients who meet specific clinical trial eligibility requirements. An example of this innovation is found in April 2024, when Citeline, a US-based business intelligence and data analytics company, introduced Citeline PatientMatch. This platform integrates advanced algorithms with extensive real-world data, including lab results, biomarkers, and electronic medical records sourced from over 400 hospitals and health systems. Its purpose is to assist sponsors and researchers in identifying eligible patients for clinical trials expeditiously and effectively, simplify patient onboarding, and facilitate intricate and varied research designs across multiple therapeutic areas.

Who Are The Key Players Driving Competition In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Read the full artificial intelligence (ai)-driven rare disease patient finder market report here:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

How Is The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Distributed Across Key Geographic Regions?

North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company

Ai In Medical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report

Artificial Intelligence Ai In Clinical Trials Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-clinical-trials-global-market-report

Artificial Intelligence In Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market At The End Of The 2026–2030 Forecast Period?

The artificial intelligence (AI)-driven rare disease patient finder market has experienced substantial expansion in recent years. This market is expected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 29.9%. The historical growth within this sector can be linked to factors such as the growing availability of electronic health records, the early integration of data analytics in clinical research, the expansion of genomic databases, an increased focus on orphan diseases, and the initial deployment of AI in trial recruitment.

The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $5.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.6%. Several factors are contributing to this growth during the forecast period, including higher investments in precision medicine research, an increasing need for more rapid clinical trial enrollment, the broadened scope of real-world evidence analytics, enhanced collaboration among healthcare and life sciences entities, and greater regulatory encouragement for innovations in rare diseases. Key trends foreseen for this period encompass the expanded deployment of AI-based patient identification algorithms, the growing incorporation of multi-source health data, increased automation in clinical trial recruitment processes, the development of precision patient matching platforms, and a heightened emphasis on facilitating rare disease research.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp

Which Market Drivers Are Supporting The Expansion Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The market for artificial intelligence (AI)-driven rare disease patient finders is anticipated to expand, driven by the growing adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments to oversee, control, and enhance health and well-being. Meanwhile, telemedicine involves providing healthcare remotely through telecommunications, utilizing tools like video consultations, mobile applications, and web platforms. This rising acceptance stems from both patients and healthcare providers seeking convenient, efficient, and easily accessible healthcare options. Artificial intelligence (AI)-driven rare disease patient finders bolster digital health and telemedicine efforts by precisely identifying patients, facilitating remote oversight, prompt virtual consultations, and tailored treatment plans. For example, in November 2025, the France-based intergovernmental organization, Organisation for Economic Co operation and Development, reported advancements in EHR access within OECD countries. Data from comparable countries showed that in 2024, the average availability of online digital health services reached 82%, an increase from 79% in 2023. Consequently, the growing embrace of digital health and telemedicine is fueling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.

What Segment Types Make Up The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

What Trends Are Advancing Progress In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the AI-driven rare disease patient finder market are prioritizing the creation of innovative technologies, specifically precision patient recruitment solutions. These efforts aim to improve the accuracy, speed, and efficiency with which suitable participants are located for rare disease clinical trials, thereby simultaneously shortening recruitment periods and elevating trial success rates. A precision patient recruitment solution represents a technology-led method that leverages sophisticated algorithms and real-world data to precisely pinpoint and connect with patients who meet specific clinical trial eligibility requirements. An example of this innovation is found in April 2024, when Citeline, a US-based business intelligence and data analytics company, introduced Citeline PatientMatch. This platform integrates advanced algorithms with extensive real-world data, including lab results, biomarkers, and electronic medical records sourced from over 400 hospitals and health systems. Its purpose is to assist sponsors and researchers in identifying eligible patients for clinical trials expeditiously and effectively, simplify patient onboarding, and facilitate intricate and varied research designs across multiple therapeutic areas.

Who Are The Key Players Driving Competition In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Read the full artificial intelligence (ai)-driven rare disease patient finder market report here:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

How Is The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Distributed Across Key Geographic Regions?

North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company

Ai In Medical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report

Artificial Intelligence Ai In Clinical Trials Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-clinical-trials-global-market-report

Artificial Intelligence In Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market At The End Of The 2026–2030 Forecast Period?

The artificial intelligence (AI)-driven rare disease patient finder market has experienced substantial expansion in recent years. This market is expected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 29.9%. The historical growth within this sector can be linked to factors such as the growing availability of electronic health records, the early integration of data analytics in clinical research, the expansion of genomic databases, an increased focus on orphan diseases, and the initial deployment of AI in trial recruitment.

The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $5.95 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 29.6%. Several factors are contributing to this growth during the forecast period, including higher investments in precision medicine research, an increasing need for more rapid clinical trial enrollment, the broadened scope of real-world evidence analytics, enhanced collaboration among healthcare and life sciences entities, and greater regulatory encouragement for innovations in rare diseases. Key trends foreseen for this period encompass the expanded deployment of AI-based patient identification algorithms, the growing incorporation of multi-source health data, increased automation in clinical trial recruitment processes, the development of precision patient matching platforms, and a heightened emphasis on facilitating rare disease research.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp

Which Market Drivers Are Supporting The Expansion Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The market for artificial intelligence (AI)-driven rare disease patient finders is anticipated to expand, driven by the growing adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments to oversee, control, and enhance health and well-being. Meanwhile, telemedicine involves providing healthcare remotely through telecommunications, utilizing tools like video consultations, mobile applications, and web platforms. This rising acceptance stems from both patients and healthcare providers seeking convenient, efficient, and easily accessible healthcare options. Artificial intelligence (AI)-driven rare disease patient finders bolster digital health and telemedicine efforts by precisely identifying patients, facilitating remote oversight, prompt virtual consultations, and tailored treatment plans. For example, in November 2025, the France-based intergovernmental organization, Organisation for Economic Co operation and Development, reported advancements in EHR access within OECD countries. Data from comparable countries showed that in 2024, the average availability of online digital health services reached 82%, an increase from 79% in 2023. Consequently, the growing embrace of digital health and telemedicine is fueling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.

What Segment Types Make Up The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –

1) By Component: Software, Services

2) By Deployment Mode: Cloud-Based, On-Premises

3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications

4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users

Subsegments:

1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System

2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades

What Trends Are Advancing Progress In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the AI-driven rare disease patient finder market are prioritizing the creation of innovative technologies, specifically precision patient recruitment solutions. These efforts aim to improve the accuracy, speed, and efficiency with which suitable participants are located for rare disease clinical trials, thereby simultaneously shortening recruitment periods and elevating trial success rates. A precision patient recruitment solution represents a technology-led method that leverages sophisticated algorithms and real-world data to precisely pinpoint and connect with patients who meet specific clinical trial eligibility requirements. An example of this innovation is found in April 2024, when Citeline, a US-based business intelligence and data analytics company, introduced Citeline PatientMatch. This platform integrates advanced algorithms with extensive real-world data, including lab results, biomarkers, and electronic medical records sourced from over 400 hospitals and health systems. Its purpose is to assist sponsors and researchers in identifying eligible patients for clinical trials expeditiously and effectively, simplify patient onboarding, and facilitate intricate and varied research designs across multiple therapeutic areas.

Who Are The Key Players Driving Competition In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?

Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.

Read the full artificial intelligence (ai)-driven rare disease patient finder market report here:

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-driven-rare-disease-patient-finder-global-market-report

How Is The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Distributed Across Key Geographic Regions?

North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp

Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2026, By The Business Research Company

Ai In Medical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report

Artificial Intelligence Ai In Clinical Trials Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-clinical-trials-global-market-report

Artificial Intelligence In Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model